CRIXIVAN

This brand name is authorized in United States. It is also authorized in Austria, Cyprus, Estonia, Lithuania, Poland, Singapore, South Africa.

Active ingredients

The drug CRIXIVAN contains one active pharmaceutical ingredient (API):

1	Indinavir UNII 771H53976Q - INDINAVIR SULFATE
	Indinavir inhibits recombinant HIV-1 and HIV-2 protease with an approximate tenfold selectivity for HIV-1 over HIV-2 proteinase. Indinavir binds reversibly to the protease active site and inhibits competitively the enzyme, thereby preventing cleavage of the viral precursor polyproteins that occurs during maturation of the newly formed viral particle.
	Read more about Indinavir

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
CRIXIVAN Hard capsule	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
J05AE02	Indinavir	J Antiinfectives for systemic use → J05 Antivirals for systemic use → J05A Direct acting antivirals → J05AE Protease inhibitors
Discover more medicines within J05AE02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1026650, 1088276, 1088287, 1088300, 1088311, 1213254
LT	Valstybinė vaistų kontrolės tarnyba	1010317, 1010322, 1028346, 1028350, 1028351
PL	Rejestru Produktów Leczniczych	100078476, 100078482
SG	Health Sciences Authority	08976P
US	FDA, National Drug Code	0006-0571, 0006-0573
ZA	Health Products Regulatory Authority	31/20.2.8/0186